PALYNZIQ

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Japan, Lithuania, Poland, United States

Active ingredients

The drug PALYNZIQ contains one active pharmaceutical ingredient (API):

1 Pegvaliase UNII N6UAH27EUV - PEGVALIASE

Pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase enzyme that converts phenylalanine to ammonia and trans-cinnamic acid that are primarily eliminated by liver metabolism. It is indicated for the treatment of patients with phenylketonuria (PKU). Read about Pegvaliase

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PALYNZIQ Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AB19		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1795989, 1795990, 1796003, 1796070
Country: FR	Base de données publique des médicaments	Identifier(s): 61661596, 65887105, 67940880
Country: IT	Agenzia del Farmaco	Identifier(s): 047940010, 047940022, 047940034, 047940046
Country: JP	医薬品医療機器総合機構	Identifier(s): 39994E9G1029, 39994E9G2025, 39994E9G3021
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1087709, 1087710, 1087711, 1087712
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100421218, 100421224, 100421230
Country: US	FDA, National Drug Code	Identifier(s): 68135-058, 68135-673, 68135-756